Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9287299 | 0.87 | KDM4E (0.34) | ADORA2AADORA1LMNA | |
| SCHEMBL6026297 | 0.87 | KMT2A (0.36) | ADORA2AADORA1 | |
| SCHEMBL15504772 | 0.82 | ADORA2A (0.32) | ADORA2AADORA1 | |
| SCHEMBL12495771 | 0.80 | ADORA2A (0.40) | ADORA2AADORA1DPP4 | |
| SCHEMBL16506516 | 0.78 | RECQL (0.34) | RECQL | |
| SCHEMBL15434656 | 0.73 | KDM4E (0.39) | LMNA | |
| SCHEMBL23053284 | 0.73 | TDP1 (0.35) | LMNA | |
| SCHEMBL12496395 | 0.73 | HRH4 (0.37) | ADORA2AADORA1 | |
| SCHEMBL8513097 | 0.73 | ADORA2A (0.36) | ADORA2AADORA1LMNA | |
| SCHEMBL2111822 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | TEON THERAPEUTICS INC (US) | 2023-01-26 | — | — | US | disclosed |
| CN-111018834-B | Aminopyrimidine butenone derivatives as PPAR-gamma modulators | 成都理工大学 | 2022-07-15 | — | — | CN | disclosed |
| CN-114667287-A | Adenosine A2A receptor antagonists and uses thereof | 泰昂治疗公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3999513-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF | Teon Therapeutics, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| US-RE48622-E1 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | disclosed |
| WO-2021011670-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS AND USES THEREOF | TEON THERAPEUTICS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| EP-2935269-B1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2018-04-11 | — | — | EP | disclosed |
| US-9714248-B2 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2017-07-25 | — | — | US | disclosed |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2016-07-07 | — | — | US | disclosed |
| EP-2935269-A1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014096423-A1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2014-06-26 | — | — | WO | disclosed |
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070111996-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-05-17 | — | — | US | disclosed |
| US-7148228-B2 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050119282-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-06-02 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | HAVCR2, TPMT, NFATC1 | ADORA2A 129/4885ADORA1 545/4885DPP4 17/4885 |
| US-20050119282-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | ADORA2A 4548/4885ADORA1 4784/4885DPP4 3319/4885 |
| US-20230024108-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA1 4/4885DPP4 3434/4885 |
| US-20070111996-A1 | Pyrazolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | ADORA2A 4548/4885ADORA1 4784/4885DPP4 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.